Ibrance decided for the health insurance benefit while Olita Tab to be decided later after Phase III clinical trial

Published: 2017-11-03 16:27:00
Updated: 2017-11-03 15:36:11

The patient sharing amount for Pfizer Pharmaceuticals Korea’s Ibrance Cap(palbociclib) will be reduced from KRW 5 million to KRW 150 thousand with approval of the national health insurance service(NHIS).

Hanmi Pharm’s Olita Tab(olmutinib) was decided to discuss about its health insurance benefit...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.